Yakira Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Yakira Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-53,818	Closed	-$544K	–	443
2022 Q4	$544K	Hold	53,818	–	–	0.11%	146
2022 Q3	$534K	Hold	53,818	–	–	0.08%	196
2022 Q2	$533K	Hold	53,818	–	–	0.08%	201
2022 Q1	$531K	Hold	53,818	–	–	0.08%	227
2021 Q4	$530K	Buy	+53,818	New	+$528K	0.07%	227

Yakira Capital Management's BIOT Position: Q1 2023 in Review

Yakira Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 53,818 shares — an estimated $544K sold.

Yakira Capital Management first reported a position in BIOT in Q4 2021 and held it in 5 quarters. The position peaked at $544K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Yakira Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Yakira Capital Management sold 53,818 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $544K.
Yakira Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 5 quarters.
Yakira Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $544K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Yakira Capital Management's 13F filing for Q1 2023, filed 12 May 2023.